[1]孟 亮 陈谦学 余小祥 涂 勤 王跃飞 樊 文 罗才奎.MS-275对原代培养的胶质瘤细胞及其干细胞生物学行为和耐药性的影响[J].中国临床神经外科杂志,2020,(06):381-385.[doi:10.13798/j.issn.1009-153X.2020.06.014]
 MENG Liang,CHEN Qian-xue,YU Xiao-xiang,et al.MS-275 regulates biological behavior and drug resistance of primary cultured glioma cells and glioma stem cells through PI3K/Akt signaling pathway[J].,2020,(06):381-385.[doi:10.13798/j.issn.1009-153X.2020.06.014]
点击复制

MS-275对原代培养的胶质瘤细胞及其干细胞生物学行为和耐药性的影响()
分享到:

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
期数:
2020年06期
页码:
381-385
栏目:
实验研究
出版日期:
2020-06-15

文章信息/Info

Title:
MS-275 regulates biological behavior and drug resistance of primary cultured glioma cells and glioma stem cells through PI3K/Akt signaling pathway
文章编号:
1009-153X(2020)06-0386-02
作者:
孟 亮 陈谦学 余小祥 涂 勤 王跃飞 樊 文 罗才奎
430061 武汉,武汉大学附属同仁医院(武汉市第三医院)神经外科(孟 亮、余小祥、涂 勤、王跃飞、樊 文、罗才奎);430060 武汉,武汉大学人民医院神经外科(陈谦学)
Author(s):
MENG Liang1 CHEN Qian-xue2 YU Xiao-xiang1 TU Qin1 WANG Yue-fei1 FAN Wen1 LUO Cai-kui1.
1. Department of Neurosurgery, Tongren Hospital of Wuhan University (Wuhan Third Hospital), Wuhan 430061, China; 2. Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
关键词:
胶质瘤胶质瘤干细胞肿瘤耐药性PI3K/Akt信号通路细胞凋亡组蛋白去乙酰化酶
Keywords:
Glioma Glioma stem cell Drug resistance PI3K/Akt signaling pathway Apoptosis Histone deacetylases inhibitor
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2020.06.014
文献标志码:
A
摘要:
目的 探讨组蛋白去乙酰化酶(HDAC)抑制剂MS-275对原代培养的胶质瘤细胞及其干细胞生物学行为和耐药性的影响。方法 取术中切除的脑胶质瘤瘤体深部无囊性变、无坏死肿瘤组织标本,分离获得胶质瘤细胞(GC)和胶质瘤干细胞(CSC),细胞分为4组:GC组,CSC组,GC+MS-275组,CSC+MS-275组。GC组和CSC组不做药物处理;GC+MS-275组和CSC+MS-275组给予MS-275处理24 h(终浓度为8 mmol/L)。检测各组细胞HDAC水平;MMT法检测细胞增殖能力;免疫印迹法检测耐药信号通路相关蛋白(ABCG2、MPR1、MPR 4、Bax、Bcl-2、PI3K、p-PI3K)的表达;流式细胞仪检测细胞周期和细胞凋亡。结果 MS-275显著降低GC和GSC中HDAC水平(P<0.05),显著抑制GC和GSC增殖能力(P<0.05),显著增加G0/G1期细胞比例和细胞凋亡率(P<0.05),显著增高GC和GSC中MPR4、ABCG2、MPR1、Bax、p-PI3K表达水平(P<0.05),而显著降低Bcl2表达水平(P<0.05)。与GC+MS-275组比较,GSC+MS-275组变化更明显(P<0.05)。结论 MS-275促进GC和CSC凋亡,而且对CSC作用更强,其机制可能与PI3K/Akt信号通路有关
Abstract:
Objective To explore the effect of histone deacetylases (HDAC) inhibitor MS-275 on the biological behavior and drug resistance of primary cultured glioma cells (GC) and glioma stem cells (GSC). Methods The specimens of gloma tissues removed during the operation were separated to obtain GC and CSC. The cells were divided into 4 groups: GC group, CSC group, GC+MS-275 group, and CSC+MS-275 group. The cells in the GC and CSC groups were not treated with MS-275. The cells in the GC+MS-275 and CSC+MS-275 groups were treated with MS-275 for 24 h with a final concentration of 8 mmol/L. The HDAC levels of cells in each group were detected. MMT method was used to detect the cell proliferation ability. Western blot method was used to detect the expression of drug resistance signal pathway related proteins including ABCG2, MPR1, MPR 4, Bax, Bcl-2, PI3K, and p-PI3K. Flow cytometry was used detect the cell cycle and apoptosis. Results MS-275 significantly reduced the HDAC levels in GC and GSC (P<0.05), significantly inhibited the proliferation ability of GC and GSC (P<0.05), significantly increased the G0/G1 phase cell ratio and apoptosis rate of GC and GSC (P<0.05), significantly increased the expression levels of MPR4, ABCG2, MPR1, Bax, and p-PI3K in GC and GSC (P<0.05), and significantly reduced the expression levels of Bcl2 in GC and GSC (P<0.05). Compared with the cells in GC+MS-275 group, the levels of HDAC and Bcl2 significantly reduced, the G0/G1 phase cell ratio and apoptosis rate, and the expression levels of MPR4, ABCG2, MPR1, Bax, and p-PI3K significantly increased in the cells of GSC+MS-275 group (P<0.05). Conclusions MS-275 may promote the apoptosis of primary cultured GC and CSC and the promotion of CSC is stronger than that of GC, which may be related to the PI3K/Akt signaling pathway

参考文献/References:

[1] Van Meir EG, Hadjipanayis CG, Norden AD, et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma [J]. Ca A Cancer J Clin, 2010, 60(3):166-193.
[2] 田 敏,张国荣. 复发脑胶质瘤的影像诊断与治疗进展[J]. 内蒙古医学杂志,2015,47(9):1057-1060.
[3] Raizer JJ, Sean Grimm MD, Chamberlain MC, et al. A phase 2 trial of single agent bevacizumab given in an every 3 weekschedule for patients with recurrent high grade gliomas [J]. Cancer, 2010, 116(22): 5297-5305.
[4] Miyazaki N, Fujiwara Y. Mutagenic and lethal effects of [5-125I]iodo-2’-deoxyuridine incorporated into DNA of mammalian cells, and their RBEs [J]. Radiat Res, 1981, 88(3): 456.
[5] 张淑悦,李玉凤,李 健. 微小RNA调控骨髓间充质干细胞成骨分化的研究进展[J]. 基因组学与应用生物学,2017,36(10):4055-4059.
[6] 姚毅武,姚和权,蒋 晟,等. 组蛋白去乙酰化酶抑制剂抗肿瘤临床研究进展[J]. 中国新药杂志,2013,22(3):294-300.
[7] 茆晨雪,周宏灏,刘昭前. 弥漫性胶质瘤生物标志物的发现及研究进展[J]. 中国临床药理学与治疗学,2016,21(1):93-98.
[8] Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells pro-mote radioresistance by preferential activation of the DNA damage response [J]. Nature, 2006, 444(7120): 756-760.
[9] 李 治,何文山,刘春萍,等. 乳腺癌干细胞放疗反应性和耐受机制的研究[J]. 中华实验外科杂志,2010,27(6):697-698.
[10] 王占东,杨 杰,郭全伟,等. 肿瘤干细胞——肿瘤治疗的新靶点[J]. 临床与实验病理学杂志,2013,29(4):427-430.
[11] Zhao J, Ma M Z, Ren H, et al. Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy [J]. Clin Cancer Res, 2013, 19(13): 3567.
[12] Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights [J]. Pharmac Therap, 2014, 143(3): 323-336.
[13] Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment [J]. Eur J Pharmac, 2009, 625(1-3): 131-142.
[14] Levine DA, Bogomolniy F, Yee CJ, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers [J]. Clin Cancer Res, 2005, 11(8): 2875-2878.
[15] Knobbe CB, Trampekieslich A, Reifenberger G. Geneticalteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblas-tomas [J]. Neuropathol App Neurobiol, 2005, 31(5): 486.
[16] Oda K, Stokoe D, Taketani Y, et al. High frequency of coex-istent mutations of PIK3CA and PTEN genes in endometrialcarcinoma [J]. Cancer Res, 2005, 65(23): 10669-10673.
[17] Hartmann W, Digonsntgerath B, Koch A, et al. Phosphati-dylinositol 3′-Kinase/AKT signaling is activated in medul-loblastoma cell proliferation and is associated with reducedexpression of PTEN [J]. Clin Cancer Res, 2006, 12(10):3019-3027.
[18] Nykern M, Tazzari PL, Finelli C, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients [J]. Leukemia, 2006, 20(2): 230-238.

相似文献/References:

[1]常英男 王 策 赵天书.SOX2基因在胶质瘤中的表达及生物学作用[J].中国临床神经外科杂志,2016,(05):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
 CHANG Ying-nan,WANG Ce,ZHAO Tian-shu..Expression of SOX2 gene and its biological role in human gliomas[J].,2016,(06):270.[doi:10.13798/j.issn.1009-153X.2016.05.005]
[2]赛 克 陈忠平.胶质瘤的疗效评价[J].中国临床神经外科杂志,2016,(06):321.[doi:10.13798/j.issn.1009-153X.2016.06.001]
[3]许 耿 路俊锋 杨 忠 施建斌 吴秋月 王 烨 庄冬晓 吴劲松.神经电生理监测技术在功能区胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
 XU Geng,LU Jun-feng,YANG Zhong,et al.Application of intraoperative neuroelectrophysiologic monitoring to gliomas resection in eloquent function brain regions[J].,2016,(06):323.[doi:10.13798/j.issn.1009-153X.2016.06.002]
[4]李剑峰 陈银生 赛 克 张湘衡 柯 超 杨群英 牟永告 许海雄 陈忠平.173例胶质瘤预后的影响因素分析[J].中国临床神经外科杂志,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
 LI Jian-feng,CHEN Yin-sheng,SAI Ke,et al.Prognostic factors for gliomas: analysis of 173 cases[J].,2016,(06):327.[doi:10.13798/j.issn.1009-153X.2016.06.003]
[5]云德波 杨宇焦 张 逵 范润金 张 渊 杜贻庆.瘤周谷氨酸、天门冬氨酸水平与胶质瘤继发性 癫痫的相关性[J].中国临床神经外科杂志,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
 YUN De-bo,YANG Yu-Jiao,ZHANG Kui,et al.Relationship of levels of glutamate and aspartate in peritumorous tissues with seizures in patients with gliomas[J].,2016,(06):331.[doi:10.13798/j.issn.1009-153X.2016.06.004]
[6]黄书岚 成于思 王 辉 汪超甲.FAK siRNA重组质粒的构建及其对胶质瘤U251细胞 增殖及侵袭能力的抑制作用[J].中国临床神经外科杂志,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
 HUANG Shu-lan,CHENG Yu-si,WANG Hui,et al.Construction of siRNA recombinant plasmid targeting focal adhesion kinase gene and its effect on the proliferation and invasiveness of human glioma U251cells[J].,2016,(06):336.[doi:10.13798/j.issn.1009-153X.2016.06.006]
[7]林 雨 张 恺 李 帅 杨学军.磁共振数字化手术单元在指导胶质瘤治疗中的作用[J].中国临床神经外科杂志,2016,(06):345.[doi:10.13798/j.issn.1009-153X.2016.06.009]
[8]戴黎明 徐成仕 王泽芬 曹长军 李志强.VEGF单抗对低氧环境下C6胶质瘤细胞侵袭性的影响[J].中国临床神经外科杂志,2016,(04):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
 DAI Li-ming,XU Cheng-shi,WANG Ze-fen,et al.Effect of nonoclonal antibody of VEGF on C6 glioma cells invasiveness under hypoxia and the role of FAK/Pyk2[J].,2016,(06):219.[doi:10.13798/j.issn.1009-153X.2016.04.009]
[9]彭泽生 田道锋 张申起 陈谦学.miR-370-3p对胶质母细胞瘤U87-MG细胞株增殖能力的影响[J].中国临床神经外科杂志,2016,(04):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
 PENG Ze-sheng,TIAN Dao-feng,ZHANG Shen-qi,et al.Effects of MircoRNA-370-3p on proliferation of glioma cell line U87-MG and its potential mechanism[J].,2016,(06):223.[doi:10.13798/j.issn.1009-153X.2016.04.010]
[10]冯 驰 郭双毅 程龙海 罗 杰.氯喹通过抑制自噬促进TRAIL诱导的胶质瘤细胞凋亡[J].中国临床神经外科杂志,2016,(04):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
 FENG Chi,GUO Shuang-yi,CHENG Long-hai,et al.Chloroquine promotes TRAIL-induced apoptosis of glioma cells through inhibition of autophagy[J].,2016,(06):227.[doi:10.13798/j.issn.1009-153X.2016.04.011]
[11]陈名宇 吴婷婷 任振华.胶质瘤干细胞表面标志物的研究进展[J].中国临床神经外科杂志,2018,(04):299.[doi:10.13798/j.issn.1009-153X.2018.04.027]

备注/Memo

备注/Memo:
(2019-08-18收稿,2019-12-17修回)基金项目:武汉市卫计委科研项目(WX17Q15)通讯作者:陈谦学,E-mail:rmyy_chenqx@163.com
更新日期/Last Update: 2020-06-15